Australasian Leukaemia & Lymphoma Group (ALLG)’s Post

It's time to #SayBloodCancer! What does it take to fight #BloodCancer? The key lies in even more personalized treatment options. This September, during #BloodCancerAwarenessMonth, we're highlighting the critical role of personalized therapies. These treatments are essential in the battle to cure blood cancer. Why? Because blood cancer isn't just one disease – it encompasses various types, such as leukemia, lymphoma, myeloma, and others. The most effective treatment approach can vary significantly based on the specific type and individual patient needs. At BMS, we are especially focused on advancing innovative therapies like CAR-T cell therapy. This approach represents a promising frontier in personalized medicine, offering new hope for patients by targeting blood cancer in a more individualized way. Let’s continue the fight against blood cancer by exploring and advancing treatment options! #BMSAustria #BMSSwitzerland Sources: BMS, lebenmitkrebs.ch

🚀 Exciting Advances in DLBCL Treatment! 🚀 Healthcare professionals, explore the cutting-edge of oncology with BiTEs and CAR-T therapies for Diffuse Large B-cell Lymphoma (DLBCL). BiTEs engage the immune system by linking T-cells to cancer cells, offering a novel approach for relapsed/refractory cases. Meanwhile, CAR-T therapy personalizes the fight against cancer by engineering patient T-cells to target and destroy lymphoma cells. 🔍 Key Considerations: - Disease characteristics & patient-specific factors - Treatment availability & logistics - Efficacy and safety profiles Stay tuned for more updates as we navigate the future of hematological malignancy treatments together! #DLBCL #BiTEs #CARTtherapy #OncologyInnovation

Conquer Lymphoma Cancer : Your Path to Recovery Your path to recovery serves as your beacon in the fight against Non-Hodgkin Lymphoma Cancer. This approach empowers you by blending top-notch medical care with whole-body therapies creating a full plan that fits your specific needs. By using cutting-edge treatments and making lifestyle shifts, you can take control of your health and build resilience. A committed team will stand by you helping you navigate this tough road with hope and self-assurance. Keep in mind, your inner strength and resolve play a crucial role in beating Lymphoma and getting back to a life full of health and energy. Use this as your guide to heal and move towards a brighter tomorrow. #ConquerLymphoma #LymphomaRecovery #CancerJourney #LymphomaAwareness #BeatCancer https://lnkd.in/eFy2Dgqb

September is Blood Cancer Awareness Month, a global🌍event dedicated to raising awareness📈and increasing understanding of #bloodcancers such as #leukaemia, #lymphoma and #myeloma.   At @4SC, we are proud to have developed our lead asset, #resminostat (#Kinselby), a novel, oral💊, maintenance treatment which has been clinically proven to improve progression free survival in advanced-stage Cutaneous T-Cell Lymphoma (CTCL), a rare type of non-Hodgkin lymphoma that affects the skin.   Learn more about blood cancers and #CTCL below 👇   #BloodCancerAwarenessMonth #BloodCancer #CutaneousTCellLymphoma

Did you know that non-Hodgkin lymphoma accounts for about 90% of all lymphoma cases diagnosed and according to the American Cancer Society is one of the most common cancers in the U.S. Learn more about non-Hodgkin lymphoma and other cancers here: https://lnkd.in/gHWmf_PH #NonHodgkinLymphoma #LymphomaAwareness #Lymphoma

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial Cancer vaccine successfully prevents recurrent lymphoma in humans. https://rupress. org/jem/article/217/9/e20191712/151871/Aut ologous-tumor-cell-vaccine-induces-antitumor -T

Fact: Over a million people every year around the world will experience the diagnosis of a blood cancer. During National Blood Cancer Awareness Month, increase your knowledge about Leukemia, Myeloma, and Lymphoma and their need for improved diagnosis, treatment, and research funding. To learn more about blood cancers and how to get involved, visit https://hubs.li/Q02NdScW0 on the National Today website. #BloodCancerAwarenessMonth #diagnostics #Leukemia #Myeloma #Lymphoma

On #WorldBloodCancerDay, we’re taking a moment to recognize the need for transformational treatments for people across the globe who are diagnosed with lymphoma, leukemia or myeloma each day. At ADC Therapeutics, we’re working with urgency to develop #antibodydrugconjugates in areas of high unmet need to bring hope to patients with #cancer, including hematologic cancers. #WBCD

May is #MelanomaAwareness & #SkinCancerPrevention Month! Did you know Cutaneous T-cell Lymphoma (CTCL) is a rare type of lymphoma that affects the skin? While it may resemble other skin conditions, early detection is key. Regularly check your skin and see a doctor for any unusual changes. At SciTech, we're committed to fighting cancers. Our drug candidate, ST-001, is currently in Phase 1 trials for lymphoma treatment. ST-001 utilizes innovative technology to deliver a promising drug called fenretinide. Stay tuned to learn more about our fight against cancer! #scitechSDP #scitechdevelopment #oncology #nanofenretinide #fenretinide #lymphoma #nonhodgkin #drugdelivery #ST001

CAR-T Cell Therapy brings a new ray of hope in the fight against cancer. It has shown unprecedented response rates in patients with B-cell leukemia and lymphoma who were no longer responding to chemotherapy. In older patients with comorbidities and patients whose Bone Marrow Transplant relapsed, CAR-T Cell Therapy can be beneficial. Dr. Esha Kaul, Director - Haematology, Hemato – Oncology & BMT, Max Institute of Cancer Care, Vaishali, Delhi, India, sheds light on the transformative benefits of this therapy in this video. Watch to know more. #CARTcellTherapy #CancerTreatment #Oncology #MaxHealthcare